Schizophrenia Clinical Trials in The Bronx, New York

5 studies are recruiting for schizophrenia in The Bronx, New York right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia

    ML-007C-MA-212 is a 52-week open-label study designed to evaluate the long-term safety, tolerability, and effectiveness of ML-007C-MA in participants with schizophrenia who have recently completed an antecedent study (ML-007C-MA-211) or enroll directly (De Novo Cohort).

    Stage
    Phase 2
    Ages
    18 to 65
    Site
    Clinical Site, The Bronx, New York
    Locations
    42 in total
    Run by
    MapLight Therapeutics

    See if you can join NCT07459647 on ClinicalTrials.gov

  2. A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Autism-Related Irritability in Adolescents, Respectively

    The purpose of this study is to evaluate the long-term safety and tolerability of KarXT and KarX-EC for the treatment of Schizophrenia and autism-related irritability in adolescents, respectively

    Stage
    Phase 3
    Ages
    5 to 17
    Site
    Local Institution - 0151, The Bronx, New York
    Locations
    91 in total
    Run by
    Karuna Therapeutics, Inc., a Bristol Myers Squibb company

    See if you can join NCT07424404 on ClinicalTrials.gov

  3. NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia

    This study will evaluate the long-term safety of NBI-1117568 in adults with schizophrenia.

    Stage
    Phase 3
    Ages
    18 to 65
    Site
    Neurocrine Clinical Sites, The Bronx, New York
    Locations
    57 in total
    Run by
    Neurocrine Biosciences

    See if you can join NCT07114874 on ClinicalTrials.gov

  4. Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia

    The main objective of the study is to evaluate NBI-1117568 compared with placebo in delaying relapse of symptoms of schizophrenia in adults who have a stable response after open-label treatment with NBI-1117568.

    Stage
    Phase 3
    Ages
    18 to 65
    Site
    Neurocrine Clinical Site, The Bronx, New York
    Locations
    20 in total
    Run by
    Neurocrine Biosciences

    See if you can join NCT07227818 on ClinicalTrials.gov

  5. NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia

    The primary objective for this study is to evaluate the efficacy of NBI-1117568 compared with placebo on improving behavioral and psychological symptoms of schizophrenia in adults.

    Stage
    Phase 3
    Ages
    18 to 65
    Site
    Neurocrine Clinical Site, The Bronx, New York
    Locations
    21 in total
    Run by
    Neurocrine Biosciences

    See if you can join NCT06963034 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.